Alopecia Areata Market Report and Forecast 2024-2032

Alopecia Areata Market Outlook

The alopecia areata market size is anticipated to grow at a CAGR of 6.3% during the forecast period of 2024-2032, driven by the increased prevalence of hair loss. The growth of the market can also be attributed to the rising efforts for finding novel and better therapies for alopecia areata.

Alopecia Areata: Introduction

Alopecia Areata is an autoimmune disease that targets hair follicles present in the human body resulting in hair loss. The most common area that gets affected by alopecia is the head. There are several sorts of alopecia areata such as patchy alopecia areata, alopecia totalis, alopecia universalis, diffuse alopecia areata, ophiasis alopecia. Some common symptoms of alopecia areata include Patches of hair loss on the affected area, including your scalp, facial hair, eyebrows, eyelashes, body hair, and nail pitting.

Alopecia Areata Market Analysis

The market growth is driven by the increasing incidence of alopecia areata. The market is further influenced by latest FDA approvals for drugs effective in alopecia treatment. For example, the leading pharmaceutical company, Pfizer Inc., received approval from the U.S. Food and Drug Administration (FDA) for LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. As it is the one and only FDA approved treatment available, the demand for LITFULO™ is expected to witness a surge in the market. Being the only FDA approved treatment available in the market, it holds the maximum advantage over the Olumiant by Eli Lilly as it covers a wider range of patients. With high demand and widespread market reach the alopecia areata market demand is expected to witness an upward trajectory in the forecast period.

Additionally, Sun Pharmaceutical Industries Ltd. recently declared the acceptance of the new drug application for deuruxolitinib by the U.S. health regulator. This is an investigational oral drug for the treatment of adults with moderate to severe alopecia areata. If approved, this could significantly impact the market by providing an alternative for patients who might not have responded well to existing treatments. Moreover, the introduction of a new drug in the alopecia treatment market could intensify competition, and further contribute to market growth.

Alopecia Areata Market Segmentations

Market Breakup by Type

• Patchy Alopecia Areata

• Alopecia Totalis

• Alopecia Universalis

• Diffuse Alopecia Areata

• Ophiasis Alopecia

• Others

Market Breakup by Diagnosis

• Trichoscopy

• Skin Biopsy

• Others

Market Breakup by Treatment

• Medical Treatments

• Natural Treatment 

• Others

Market Breakup by Route of Administration

• Oral

• Parenteral

• Others

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Alopecia Areata Market Overview

The alopecia areata market growth is driven by the increasing incidence of alopecia areata. Another significant factor driving the market growth is the rising healthcare expenditure due to which the healthcare facilities are advancing and adopting advanced technologies. The increasing focus of scientists on finding novel and better therapies for alopecia areata has been continuously resulting in a substantial rise in research and development in the field.

Pharmaceutical and biotech companies have an opportunity to fill a crucial gap of unmet needs by creating novel treatments targeting symptoms and potential causes of alopecia areata and encouraging hair regeneration. The substantial growth of awareness among people and patients has led to an increased number of diagnoses for early detection and treatment. This has significantly contributed to the rising alopecia areata market share.

The United States is dominating the regional market due to the increase in surgical hair transplantation among patients suffering from Alopecia areata. The increasing demand for surgical hair transplants has introduced new opportunities for hair restoration clinics. The increasing adoption of advanced technologies in the region is a major factor driving the market growth.

Alopecia Areata Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Johnson & Johnson Services, Inc 

• Merck & Co., Inc. 

• Cipla Limited 

• GlaxoSmithKline plc 

• Viatris Inc. 

• Pfizer, Inc. 

• Curallux, LLC. 

• Apira Science Inc. 

• Revian Inc. 

• Theradome 

• Bausch Health Companies Inc.  

• Perrigo Company plc 

• LEO Pharma A/S 

• Hikma Pharmaceuticals PLC  

• Baxter

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Alopecia Areata Market Report Snapshots

Alopecia Areata Market Size

Alopecia Areata Analysis

Alopecia Areata Treatment Companies